Hasan Ongun Onaran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hasan Ongun Onaran has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Ozlem Ugur
Department of Biophysics (M.U.) and Department of Pharmacology (O.U.), Faculty of Medicine, Ankara University, Ankara, Turkey
9 shared publications - Tommaso Costa
Department of Pharmacology, Istituto Superiore di Sanità, Rome, Italy
9 shared publications - Caterina Ambrosio
National Center for Drug Research and Evaluation, National Institute of Health, 00161 Rome, Italy
3 shared publications Hakan Gürdal
Ankara University Faculty of Medicine, Department of Pharmacology and Clinical Pharmacology, Sihhiye 06100, Ankara, Turkey
3 shared publications- Kemal Sayar
Ankara University, Faculty of Medicine, Department of Pharmacology and Clinical Pharmacology, Ankara, Turkey
3 shared publications - Sudarshan Rajagopal
Department of Biochemistry, Duke University School of Medicine
3 shared publications
Latest Publications
- Open Access
- 11 February 2024
- Published by Wiley in British Journal of Pharmacology
- Vol. 181 (12) , 1757-1767
Why classical receptor theory, which ignores allostery, can effectively measure the strength of an allosteric effect as agonist's efficacy
Background and PurposeThe classical theory of receptor action has been used for decades as a powerful tool to estimate molecular determinants of ligand-induced receptor activation (i.e., affinity and efficacy) from experimentally observable biological responses. However, it is also a well-recognized fact that the receptor-binding and activation mechanisms, and the parameters thereof, described in the classical theory contradict with the modern view of receptor activation based on allosteric principles.Experimental ApproachWe used mathematical analysis, along with some numerical simulations, to answer the key question as to what extent the classical theory is compatible-if at all-with the modern understanding of receptor activation.Key ResultsHere, we showed conclusively that (1) receptor activation equations based on allosteric principles contain the logic of the classical theory in disguise, and therefore, (2) estimates of "intrinsic efficacy" (epsilon) obtained by means of classical techniques (i.e., null methods or fitting the operational model to concentration-response data) are equivalent to the allosteric coupling factors that represent the molecular efficacy of ligands.Conclusion and ImplicationsThus, we conclude that despite the justified criticisms it has received so far, the classical theory may continue to be useful in estimating ligand efficacy from experimental data, if used properly. Here, we also provide rigorous criteria for the proper use of the theory. These findings not only have implications for ligand classification but also resolve some long lasting discussions in the field of bias agonism in GPCR, which requires reasonable estimates of relative ligand efficacies at different signalling pathways.
- 11 February 2024
- Published by Wiley in British Journal of Pharmacology
- Vol. 181 (12) , 1757-1767
Open AccessWhy classical receptor theory, which ignores allostery, can effectively measure the strength of an allosteric effect as agonist's efficacy
Background and PurposeThe classical theory of receptor action has been used for decades as a powerful tool to estimate molecular determinants of ligand-induced receptor activation (i.e., affinity and efficacy) from experimentally observable biological responses. However, it is also a well-recognized fact that the receptor-binding and activation mechanisms, and the parameters thereof, described in the classical theory contradict with the modern view of receptor activation based on allosteric principles.Experimental ApproachWe used mathematical analysis, along with some numerical simulations, to answer the key question as to what extent the classical theory is compatible-if at all-with the modern understanding of receptor activation.Key ResultsHere, we showed conclusively that (1) receptor activation equations based on allosteric principles contain the logic of the classical theory in disguise, and therefore, (2) estimates of "intrinsic efficacy" (epsilon) obtained by means of classical techniques (i.e., null methods or fitting the operational model to concentration-response data) are equivalent to the allosteric coupling factors that represent the molecular efficacy of ligands.Conclusion and ImplicationsThus, we conclude that despite the justified criticisms it has received so far, the classical theory may continue to be useful in estimating ligand efficacy from experimental data, if used properly. Here, we also provide rigorous criteria for the proper use of the theory. These findings not only have implications for ligand classification but also resolve some long lasting discussions in the field of bias agonism in GPCR, which requires reasonable estimates of relative ligand efficacies at different signalling pathways.
- Open Access
- 14 September 2023
- Published by Wiley
Why classical receptor theory, which ignores allostery, can effectively measure the strength of an allosteric effect underlying the ligand efficacy
Background and Purpose: The classical theory of receptor action has been used for decades as a powerful tool to estimate molecular determinants of ligand-induced receptor activation (i.e. affinity and efficacy) from experimentally observable biological responses. However, it is also a well-recognized fact that the receptor-binding and activation mechanisms, and the parameters thereof, described in the classical theory contradict with the modern view of receptor activation based on allosteric principles. Experimental Approach: We used mathematical analysis, along with some numerical simulations, to answer the key question as to what extent the classical theory is compatible -if at all- with the modern understanding of receptor activation. Key Results: Here, we showed conclusively that 1) receptor activation equations based on allosteric principles contain the logic of the classical theory in disguise, and therefore, 2) estimates of “intrinsic efficacy” () obtained by means of classical techniques (i.e. null methods or fitting the operational model to concentration-response data) are equivalent to the allosteric coupling factors that represent the molecular efficacy of ligands. Conclusion and Implications: Thus, we conclude that despite the right criticisms it has received so far, the classical theory may continue to be useful in estimating ligand efficacy from experimental data, if used properly. Here, we also provide rigorous criteria for the proper use of the theory. These findings not only have implications on ligand classification, but also resolve some long lasting discussions in the field of bias agonism in GPCR, which requires reasonable estimates of relative ligand efficacies at different signalling pathways.
- 14 September 2023
- Published by Wiley
Open AccessWhy classical receptor theory, which ignores allostery, can effectively measure the strength of an allosteric effect underlying the ligand efficacy
Background and Purpose: The classical theory of receptor action has been used for decades as a powerful tool to estimate molecular determinants of ligand-induced receptor activation (i.e. affinity and efficacy) from experimentally observable biological responses. However, it is also a well-recognized fact that the receptor-binding and activation mechanisms, and the parameters thereof, described in the classical theory contradict with the modern view of receptor activation based on allosteric principles. Experimental Approach: We used mathematical analysis, along with some numerical simulations, to answer the key question as to what extent the classical theory is compatible -if at all- with the modern understanding of receptor activation. Key Results: Here, we showed conclusively that 1) receptor activation equations based on allosteric principles contain the logic of the classical theory in disguise, and therefore, 2) estimates of “intrinsic efficacy” () obtained by means of classical techniques (i.e. null methods or fitting the operational model to concentration-response data) are equivalent to the allosteric coupling factors that represent the molecular efficacy of ligands. Conclusion and Implications: Thus, we conclude that despite the right criticisms it has received so far, the classical theory may continue to be useful in estimating ligand efficacy from experimental data, if used properly. Here, we also provide rigorous criteria for the proper use of the theory. These findings not only have implications on ligand classification, but also resolve some long lasting discussions in the field of bias agonism in GPCR, which requires reasonable estimates of relative ligand efficacies at different signalling pathways.
- Top Cited PapersOpen Access
- 27 March 2022
- Published by Wiley in British Journal of Pharmacology
- Vol. 179 (14) , 3651-3674
Community guidelines for GPCR ligand bias: IUPHAR review 32
G protein-coupled receptors modulate a plethora of physiological processes and mediate the effects of one-third of FDA-approved drugs. Depending on which ligand activates a receptor, it can engage different intracellular transducers. This ‘biased signaling’ paradigm requires that we now characterize physiological signaling not just by receptors but by ligand-receptor pairs. Ligands eliciting biased signaling may constitute better drugs with higher efficacy and fewer adverse effects. However, ligand bias is very complex, making reproducibility and description challenging. Here, we provide guidelines and terminology for any scientists to design and report ligand bias experiments. The guidelines will aid consistency and clarity, as the basic receptor research and drug discovery communities continue to advance our understanding and exploitation of ligand bias. Scientific insight, biosensors, and analytical methods are still evolving and should benefit from and contribute to the implementation of the guidelines, together improving translation from in vitro to disease-relevant in vivo models.
- 27 March 2022
- Published by Wiley in British Journal of Pharmacology
- Vol. 179 (14) , 3651-3674
Top Cited PapersOpen AccessCommunity guidelines for GPCR ligand bias: IUPHAR review 32
G protein-coupled receptors modulate a plethora of physiological processes and mediate the effects of one-third of FDA-approved drugs. Depending on which ligand activates a receptor, it can engage different intracellular transducers. This ‘biased signaling’ paradigm requires that we now characterize physiological signaling not just by receptors but by ligand-receptor pairs. Ligands eliciting biased signaling may constitute better drugs with higher efficacy and fewer adverse effects. However, ligand bias is very complex, making reproducibility and description challenging. Here, we provide guidelines and terminology for any scientists to design and report ligand bias experiments. The guidelines will aid consistency and clarity, as the basic receptor research and drug discovery communities continue to advance our understanding and exploitation of ligand bias. Scientific insight, biosensors, and analytical methods are still evolving and should benefit from and contribute to the implementation of the guidelines, together improving translation from in vitro to disease-relevant in vivo models.
- Open Access
- 25 September 2021
- Published by Wiley
International Union of Basic and Clinical Pharmacology. Guidelines for GPCR ligand bias
G protein-coupled receptors modulate a plethora of physiological processes and mediate the effects of one-third of FDA-approved drugs. Notably, depending on which ligand has activated a particular receptor, it can engage different intracellular transducers. This paradigm of ligand-dependent ‘biased signaling’ dictates a need to advance beyond the level of receptors to consider the combined ligand-receptor pair in order to understand physiological signaling. Bias signaling also has the potential to improve medicines by reducing adverse effects. However, this is challenged by inconsistent interpretation of results and lack of commonly agreed guidelines. Here, we present recommended terminology and guidelines to conduct, report and quantify bias in a comparable and reproducible fashion. We expect these recommendations will facilitate a common understanding of experiments and findings across basic receptor research and drug discovery, while the area and the analytical methods to measure bias are still evolving, especially in complex cellular, tissue and organismal systems.
- 25 September 2021
- Published by Wiley
Open AccessInternational Union of Basic and Clinical Pharmacology. Guidelines for GPCR ligand bias
G protein-coupled receptors modulate a plethora of physiological processes and mediate the effects of one-third of FDA-approved drugs. Notably, depending on which ligand has activated a particular receptor, it can engage different intracellular transducers. This paradigm of ligand-dependent ‘biased signaling’ dictates a need to advance beyond the level of receptors to consider the combined ligand-receptor pair in order to understand physiological signaling. Bias signaling also has the potential to improve medicines by reducing adverse effects. However, this is challenged by inconsistent interpretation of results and lack of commonly agreed guidelines. Here, we present recommended terminology and guidelines to conduct, report and quantify bias in a comparable and reproducible fashion. We expect these recommendations will facilitate a common understanding of experiments and findings across basic receptor research and drug discovery, while the area and the analytical methods to measure bias are still evolving, especially in complex cellular, tissue and organismal systems.
- 1 July 2021
- Published by Elsevier in Cellular Signalling
- Vol. 83, 109981
Biased agonism at G protein-coupled receptors
- 1 July 2021
- Published by Elsevier in Cellular Signalling
- Vol. 83, 109981
Biased agonism at G protein-coupled receptors
- 1 June 2021
- Published by Elsevier in Cellular Signalling
- Vol. 82, 109955
Conceptual and experimental issues in biased agonism
- 1 June 2021
- Published by Elsevier in Cellular Signalling
- Vol. 82, 109955
Conceptual and experimental issues in biased agonism
- Open Access
- 14 March 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , srep44247
Systematic errors in detecting biased agonism: Analysis of current methods and development of a new model-free approach
Discovering biased agonists requires a method that can reliably distinguish the bias in signalling due to unbalanced activation of diverse transduction proteins from that of differential amplification inherent to the system being studied, which invariably results from the non-linear nature of biological signalling networks and their measurement. We have systematically compared the performance of seven methods of bias diagnostics, all of which are based on the analysis of concentration-response curves of ligands according to classical receptor theory. We computed bias factors for a number of β-adrenergic agonists by comparing BRET assays of receptor-transducer interactions with Gs, Gi and arrestin. Using the same ligands, we also compared responses at signalling steps originated from the same receptor-transducer interaction, among which no biased efficacy is theoretically possible. In either case, we found a high level of false positive results and a general lack of correlation among methods. Altogether this analysis shows that all tested methods, including some of the most widely used in the literature, fail to distinguish true ligand bias from “system bias” with confidence. We also propose two novel semi quantitative methods of bias diagnostics that appear to be more robust and reliable than currently available strategies.
- 14 March 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , srep44247
Open AccessSystematic errors in detecting biased agonism: Analysis of current methods and development of a new model-free approach
Discovering biased agonists requires a method that can reliably distinguish the bias in signalling due to unbalanced activation of diverse transduction proteins from that of differential amplification inherent to the system being studied, which invariably results from the non-linear nature of biological signalling networks and their measurement. We have systematically compared the performance of seven methods of bias diagnostics, all of which are based on the analysis of concentration-response curves of ligands according to classical receptor theory. We computed bias factors for a number of β-adrenergic agonists by comparing BRET assays of receptor-transducer interactions with Gs, Gi and arrestin. Using the same ligands, we also compared responses at signalling steps originated from the same receptor-transducer interaction, among which no biased efficacy is theoretically possible. In either case, we found a high level of false positive results and a general lack of correlation among methods. Altogether this analysis shows that all tested methods, including some of the most widely used in the literature, fail to distinguish true ligand bias from “system bias” with confidence. We also propose two novel semi quantitative methods of bias diagnostics that appear to be more robust and reliable than currently available strategies.
- 18 November 2016
- Published by Royal Society of Chemistry (RSC)
- p. 131-155
A Unifying Approach to the Duality of “Energetic”Versus“Conformational” Formulations of Allosteric Coupling: Mechanistic Implications for GPCR Allostery
Allostery means that a perturbation at one region of a protein affects the functioning at a distant region of the molecule; it is the keystone principle by which proteins work and are regulated in living cells. As we briefly review here, many different structural–dynamic processes can produce the same type of allosteric effect. Thus, allosteric regulation is a general principle in terms of protein thermodynamics, not just a molecular mechanism. In phenomenological models of allostery this principle generates a duality of definitions with diverse mechanistic implications, namely: allosteric coupling between binding sites versus changes across allosteric conformations. We outline here a unified conceptual framework that can merge the two definitions into a single vision. By focusing on the family of G-protein-coupled receptors, we use this approach to analyze the relationship between allostery and structure. We also propose describing allosteric transitions as altered probability distributions of possible physical states rather than as changed equilibria within collections of allosteric states with sparsely distributed levels of function. This non-deterministic view of protein behaviour helps with visualizing how undetectable structural differences may still play a key role in determining the size of allosteric coupling.
- 18 November 2016
- Published by Royal Society of Chemistry (RSC)
- p. 131-155
A Unifying Approach to the Duality of “Energetic”Versus“Conformational” Formulations of Allosteric Coupling: Mechanistic Implications for GPCR Allostery
Allostery means that a perturbation at one region of a protein affects the functioning at a distant region of the molecule; it is the keystone principle by which proteins work and are regulated in living cells. As we briefly review here, many different structural–dynamic processes can produce the same type of allosteric effect. Thus, allosteric regulation is a general principle in terms of protein thermodynamics, not just a molecular mechanism. In phenomenological models of allostery this principle generates a duality of definitions with diverse mechanistic implications, namely: allosteric coupling between binding sites versus changes across allosteric conformations. We outline here a unified conceptual framework that can merge the two definitions into a single vision. By focusing on the family of G-protein-coupled receptors, we use this approach to analyze the relationship between allostery and structure. We also propose describing allosteric transitions as altered probability distributions of possible physical states rather than as changed equilibria within collections of allosteric states with sparsely distributed levels of function. This non-deterministic view of protein behaviour helps with visualizing how undetectable structural differences may still play a key role in determining the size of allosteric coupling.
- 1 December 2014
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 35 (12) , 639-647
What is biased efficacy? Defining the relationship between intrinsic efficacy and free energy coupling
- 1 December 2014
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 35 (12) , 639-647
What is biased efficacy? Defining the relationship between intrinsic efficacy and free energy coupling
- Open Access
- 1 August 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (33) , 23964-23978
Ligands Raise the Constraint That Limits Constitutive Activation in G Protein-coupled Opioid Receptors
- 1 August 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (33) , 23964-23978
Open AccessLigands Raise the Constraint That Limits Constitutive Activation in G Protein-coupled Opioid Receptors